Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
101.50
+3.63 (3.71%)
At close: Jul 30, 2026, 4:00 PM EDT
101.00
-0.50 (-0.49%)
After-hours: Jul 30, 2026, 7:54 PM EDT
[Name] Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
112
Market Cap
8.93B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
| Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
| Dec 31, 2021 | 18.74M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.51B |
| Ionis Pharmaceuticals | 1.06B |
| TG Therapeutics | 700.35M |
| Rhythm Pharmaceuticals | 217.17M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
| Crinetics Pharmaceuticals | 18.07M |
| Praxis Precision Medicines | 7.46M |
SYRE News
- 2 days ago - Spyre Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research - TheFly
- 17 days ago - Spyre Therapeutics price target raised to $120 from $84 at Mizuho - TheFly
- 4 weeks ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 4 weeks ago - Spyre Therapeutics files automatic mixed securities shelf - TheFly
- 5 weeks ago - Biotech ETF Index Surges 10% After Rebalance - ETF Trends
- 5 weeks ago - Spyre Therapeutics price target raised to $135 from $115 at Deutsche Bank - TheFly
- 6 weeks ago - Spyre Therapeutics price target raised to $100 from $80 at Wedbush - TheFly
- 6 weeks ago - Spyre Therapeutics price target raised to $112 from $98 at BTIG - TheFly